Phase I dose escalating trial of Velcade [bortezomib] (PS-341) in combination with idarubicin and cytosine arabinoside [cytarabin] in patients with acute myelogenous leukemia.
Phase of Trial: Phase I
Latest Information Update: 05 Feb 2010
At a glance
- Drugs Bortezomib; Cytarabine; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 05 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Feb 2010 Actual end date (Sep 2005) added as reported by ClinicalTrials.gov.
- 14 Aug 2007 New trial record.